Telix Pharmaceuticals (TLX) Goodwill (2024 - 2025)

Telix Pharmaceuticals (TLX) posted Goodwill of $199.0 million for Q4 2025, up 198.84% on a QoQ basis from $66.6 million in Q4 2024, and up 198.84% year-over-year from $66.6 million in Q4 2024.

Telix Pharmaceuticals (TLX) has 2 years of Goodwill data on file, last reported at $199.0 million in Q4 2025.

  • In Q4 2025, Goodwill rose 198.84% year-over-year to $199.0 million; the TTM figure through Dec 2025 stood at $199.0 million (up 198.84% YoY), while the FY2025 annual figure was $199.0 million, up 198.84% from the prior year.
  • Goodwill advanced to $199.0 million in Q4 2025, from $66.6 million in the prior quarter.
  • Across five years, Goodwill topped out at $199.0 million in Q4 2025 and bottomed at $66.6 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Telix Pharmaceuticals 4.52 Bn 4.38 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 198.99 Mn
Dec 31, 2024 66.59 Mn